|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 199.96 USD | +2.94% |
|
+2.04% | +13.62% |
| Jun. 08 | Needham Upgrades Biogen to Buy From Hold, Price Target is $255 | MT |
| Jun. 04 | Biogen Receives FDA Breakthrough Therapy Designation for Salanersen for Spinal Muscular Atrophy | CI |
Main competitors
| Capi.($) | Investor | ESG MSCI | Fundamentals | Financial revisions | Global Valuation | Visibility | Consensus | ||
|---|---|---|---|---|---|---|---|---|---|
 | 28.68B | AA | |||||||
| 61.21B | BBB | |||||||
| 58.15B | AA | |||||||
| 39.54B | BBB | |||||||
| 35.08B | A | |||||||
| 21.06B | AA | |||||||
| 18.25B | - | BBB | - | - | ||||
| 16.49B | AAA | |||||||
| 15.87B | AA | |||||||
| 13.2B | - | BB | - | - | ||||
| 12.68B | - | BBB | - | - | ||||
| 11.1B | CCC | |||||||
| 10.86B | BBB | - | ||||||
| 9.21B | - | B | - | - | ||||
| 6.28B | BB | |||||||
| 5.79B | - | BB | - | - | - | |||
| 5.26B | A | |||||||
| 5.09B | - | B | - | - | - | - | - | |
| 5.05B | - | - | - | - | - | |||
| 4.93B | - | - | ||||||
| Average | 19.19B | A | |||||||
| Weighted average by Cap. | A |
- Stock Market
- Stocks
- BIIB Stock
- Sector Biogen Inc.
- Sector ratings
Select your edition
All financial news and data tailored to specific country editions
